p73, a member of the p53 family, exhibits activities similar to those of p53, including the ability to induce growth arrest and apoptosis. p73 influences chemotherapeutic responses in human cancer patients, in association with p53. Alternative splicing of the TP73 gene produces many p73 C- and N-terminal isoforms, which vary in their transcriptional activity towards p53-responsive promoters. In this paper, we show that the C-terminal spliced isoforms of the p73 protein differ in their DNA-binding capacity, but this is not an accurate predictor of transcriptional activity. In different p53-null cell lines, p73beta induces either mitochondrial-associated or death receptor-mediated apoptosis, and these differences are reflected in different gene expression profiles. In addition, p73 induces cell cycle arrest and p21(WAF1) expression in H1299 cells, but not in Saos-2. This data shows that TAp73 isoforms act differently depending on the tumour cell background, and have important implications for p73-mediated therapeutic responses in individual human cancer patients.

Department of Oncological and Experimental Pathology Masaryk Memorial Cancer Institute Brno Czech Republic

Zobrazit více v PubMed

Murray-Zmijewski F., Lane D.P., Bourdon J.C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006;13:962–972. doi: 10.1038/sj.cdd.4401914. PubMed DOI

Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–819. doi: 10.1016/S0092-8674(00)80540-1. PubMed DOI

Melino G., De Laurenzi V., Vousden K.H. p73: Friend or foe in tumorigenesis. Nat. Rev. Cancer. 2002;2:605–615. doi: 10.1038/nrc861. PubMed DOI

Dominguez G., Garcia J.M., Pena C., Silva J., Garcia V., Martinez L., Maximiano C., Gomez M.E., Rivera J.A., Garcia-Andrade C., Bonilla F. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J. Clin. Oncol. 2006;24:805–815. doi: 10.1200/JCO.2005.02.2350. PubMed DOI

Concin N., Becker K., Slade N., Erster S., Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., Moll U.M. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 2004;64:2449–2460. doi: 10.1158/0008-5472.CAN-03-1060. PubMed DOI

Deyoung M.P., Ellisen L.W. p63 and p73 in human cancer: defining the network. Oncogene. 2007;26:5169–5183. doi: 10.1038/sj.onc.1210337. PubMed DOI

Coates P.J. Regulating p73 isoforms in human tumours. J. Pathol. 2006;210:385–389. doi: 10.1002/path.2080. PubMed DOI

Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–564. doi: 10.1038/416560a. PubMed DOI

Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., Kaelin W.G., Jr. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403–410. doi: 10.1016/S1535-6108(03)00078-3. PubMed DOI

Rocco J.W., Leong C.O., Kuperwasser N., DeYoung M.P., Ellisen L.W. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006;9:45–56. doi: 10.1016/j.ccr.2005.12.013. PubMed DOI

Vojtesek B., Bartek J., Midgley C.A., Lane D.P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 1992;151:237–244. doi: 10.1016/0022-1759(92)90122-A. PubMed DOI

Chen J., Marechal V., Levine A.J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 1993;13:4107–4114. PubMed PMC

Fredersdorf S., Milne A.W., Hall P.A., Lu X. Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. Am. J. Pathol. 1996;148:825–835. PubMed PMC

Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. U S A. 1987;84:7716–7719. doi: 10.1073/pnas.84.21.7716. PubMed DOI PMC

Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992;7:743–749. PubMed

Sambrook, J., Fritsch, E.F. and Maniatis, T. Assay for β-Galactosidase in Extracts of Mammalian Cells. in: Molecular cloning, 2th edition, Cold Spring Harbor Laboratory Press, 1989, 16.66–16.67.

Thurfjell N., Coates P.J., Uusitalo T., Mahani D., Dabelsteen E., Dahlqvist A., Sjostrom B., Roos G., Nylander K. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int. J. Oncol. 2004;25:27–35. PubMed

Boldrup L., Bourdon J.C., Coates P.J., Sjostrom B., Nylander K. Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur. J. Cancer. 2007;43:617–623. doi: 10.1016/j.ejca.2006.10.019. PubMed DOI PMC

Lohr K., Moritz C., Contente A., Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 2003;278:32507–32516. doi: 10.1074/jbc.M212517200. PubMed DOI

Grob T.J., Novak U., Maisse C., Barcaroli D., Luthi A.U., Pirnia F., Hugli B., Graber H.U., De Laurenzi V., Fey M.F., Melino G., Tobler A. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell. Death. Differ. 2001;8:1213–1223. doi: 10.1038/sj.cdd.4400962. PubMed DOI

Ueda Y., Hijikata M., Takagi S., Chiba T., Shimotohno K. Transcriptional activities of p73 splicing variants are regulated by intervariant association. Biochem. J. 2001;356:859–866. doi: 10.1042/0264-6021:3560859. PubMed DOI PMC

Brazda V., Muller P., Brozkova K., Vojtesek B. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Biochem. Biophys. Res. Commun. 2006;351:499–506. doi: 10.1016/j.bbrc.2006.10.065. PubMed DOI

Bernassola F., Salomoni P., Oberst A., Di Como C.J., Pagano M., Melino G., Pandolfi P.P. Ubiquitin-dependent degradation of p73 is inhibited by PML. J. Exp. Med. 2004;199:1545–1557. doi: 10.1084/jem.20031943. PubMed DOI PMC

Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., George D.L. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes. Dev. 1999;13:2490–2501. doi: 10.1101/gad.13.19.2490. PubMed DOI PMC

Lanza M., Marinari B., Papoutsaki M., Giustizieri M.L., D'Alessandra Y., Chimenti S., Guerrini L., Costanzo A. Cross-talks in the p53 family: deltaNp63 is an anti-apoptotic target for deltaNp73alpha and p53 gain-offunction mutants. Cell Cycle. 2006;5:1996–2004. PubMed

Terrasson J., Allart S., Martin H., Lule J., Haddada H., Caput D., Davrinche C. p73-dependent apoptosis through death receptor: impairment by human cytomegalovirus infection. Cancer Res. 2005;65:2787–2794. doi: 10.1158/0008-5472.CAN-04-2019. PubMed DOI

Glasgow J.N., Qiu J., Rassin D., Grafe M., Wood T., Perez-Pol J.R. Transcriptional regulation of the BCL-X gene by NF-kappaB is an element of hypoxic responses in the rat brain. Neurochem. Res. 2001;26:647–659. doi: 10.1023/A:1010987220034. PubMed DOI

Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell. 2003;3:17–22. doi: 10.1016/S1535-6108(02)00241-6. PubMed DOI